Compare TNXP & ELME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNXP | ELME |
|---|---|---|
| Founded | 2007 | 1960 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.7M | 191.9M |
| IPO Year | 2008 | 1994 |
| Metric | TNXP | ELME |
|---|---|---|
| Price | $13.47 | $1.66 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $12.67 |
| AVG Volume (30 Days) | 425.9K | ★ 653.2K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 707.44% |
| EPS Growth | ★ 91.75 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $13,107,000.00 | ★ $206,360,000.00 |
| Revenue This Year | $558.11 | $5.03 |
| Revenue Next Year | $38.29 | $4.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 29.85 | N/A |
| 52 Week Low | $9.40 | $1.26 |
| 52 Week High | $34.00 | $17.68 |
| Indicator | TNXP | ELME |
|---|---|---|
| Relative Strength Index (RSI) | 59.03 | 61.52 |
| Support Level | $11.98 | $1.46 |
| Resistance Level | $13.36 | $2.06 |
| Average True Range (ATR) | 0.79 | 0.02 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 60.55 | 87.50 |
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located near transportation nodes. It derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Elme Communities' tenants are banking, consulting, law, and financial services firms. The company operates in a single reportable segment which includes the ownership, development, redevelopment and acquisition of apartment communities.